Traditional Cryoprecipitate + Pathogen-Reduced Cryoprecipitate
ApprovedCompleted 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Hypofibrinogenemia
Conditions
Hypofibrinogenemia, Bleeding
Trial Timeline
Apr 1, 2023 → Oct 3, 2025
NCT ID
NCT05711524About Traditional Cryoprecipitate + Pathogen-Reduced Cryoprecipitate
Traditional Cryoprecipitate + Pathogen-Reduced Cryoprecipitate is a approved stage product being developed by Cerus for Hypofibrinogenemia. The current trial status is completed. This product is registered under clinical trial identifier NCT05711524. Target conditions include Hypofibrinogenemia, Bleeding.
Hype Score Breakdown
Clinical
30
Activity
20
Company
2
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05711524 | Approved | Completed |
Competing Products
1 competing product in Hypofibrinogenemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Pathogen Reduced Cryoprecipitated Fibrinogen Complex + Cryoprecipitated-Antihemophilic Factor | Cerus | Pre-clinical | 15 |
Other Products from Cerus
Pathogen-Reduced Plasma + Crystalloid SolutionsApproved
77
S-303 Treated Red Blood Cells (RBCs) + Conventional, untreated Red Blood CellsPhase 3
69
S-303 Red Blood Cells (RBCs) - Test + Conventional, untreated red blood cells (RBCs) - ControlPhase 3
69
Autologous apheresis Platelet Components, prepared with the INTERCEPT Blood System for Platelets. + Autologous apheresis Conventional untreated Platelet ComponentsPhase 2
44
INTERCEPT treated plateletsPhase 2
44